GLUE - Monte Rosa Therapeutics, Inc.

Stock Grade Analysis

General Rating

B+
Overall Score: 3/5
Multi-dimensional Scores
DCF: 4/5 ROE: 3/5 ROA: 4/5 D/E: 3/5 P/E: 2/5
Financial Ratios Trend

Grades Consensus

0

Strong Buy

7

Buy

2

Hold

0

Sell

0

Strong Sell

Buy

Consensus

Grade News & Updates

Date Grading Company New Grade Previous Grade Action Price When Posted News Title Publisher
2026-01-07 Jefferies Buy Buy Hold $22.95 Monte Rosa Therapeutics price target raised to $31 from $22… TheFly
2026-01-07 Cowen & Co. Buy Buy Hold $23.28 TD Cowen on Monte Rosa Therapeutics (GLUE): 'the overall da… StreetInsider
2026-01-07 Wedbush Outperform Outperform Hold $24.4357 Monte Rosa Therapeutics price target raised to $37 from $26… TheFly
2025-12-17 Jefferies Buy Buy Hold $18.66 Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies StreetInsider
2025-12-16 Wells Fargo Overweight Overweight Upgrade $16.45 Monte Rosa Therapeutics upgraded to Overweight from Equal W… TheFly
2024-10-28 Cowen & Co. Buy Buy Hold $9.7568 TD Cowen Reiterates Buy Rating on Monte Rosa Therapeutics (… StreetInsider
2024-10-28 Piper Sandler Overweight Overweight Hold $11.45 Monte Rosa Therapeutics price target raised to $20 from $16… TheFly
2024-08-12 Wells Fargo Overweight Overweight Hold $3.94 Monte Rosa Therapeutics price target lowered to $17 from $1… TheFly
2024-06-28 Cowen & Co. Buy Buy Hold $3.74 TD Cowen Reiterates Buy Rating on Monte Rosa Therapeutics (… StreetInsider
2024-06-28 Piper Sandler Overweight Overweight Hold $3.74 Piper Sandler Reiterates Overweight Rating on Monte Rosa Th… StreetInsider